Activation of ABCA1 with LXR or RXR agonists increase the lipidation of ApoE4, reverses the ApoE4-driven accumulation of Aβ and tau hyperphosphorylation in hippocampal neurons, as well as improving the impairment of neuron synapses and cognition in AD mouse models [26,27,28]. Here, MAPT is linked to Alzheimer disease.